Why is RxFul pricing hard to see before you commit?

The pricing transparency problem shows up when a patient is ready to start semaglutide or tirzepatide and you still do not know your all-in per-vial cost. RxFul publishes monthly platform tiers on rxful.com, but those tiers gate catalog breadth — GLP-only on the free plan, full formulary from $997/mo — and Silver adds volume-based fulfillment pricing. The monthly fee is visible; the landed drug cost you need for margin may not be until you are inside the product.

For owners, the opacity makes cash-pay program planning a moving target. If per-vial 503A cost is bundled into tiered SaaS and volume fulfillment, building predictable patient pricing means working from estimates rather than numbers you can see in catalog and cart before checkout.

RxFul's model separates platform access from drug economics. Rx-GLP ($0/mo) limits you to GLP products with a standard white-label template. Rx-Bronze ($997/mo) unlocks main catalog access. Rx-Silver ($1,497/mo) introduces volume-based fulfillment pricing on top of the monthly fee. Rx-Gold ($1,997/mo) adds dedicated onboarding and advanced reporting. Each step changes what you can order and what you pay — but none of that replaces seeing resolved per-vial 503A cost on the line before you quote a patient.

When you evaluate RxFul, ask for written per-vial landed cost on your top five SKUs at the tier you plan to buy, including platform fee and fulfillment, and whether that number appears inside the ordering tool after onboarding. If pricing never surfaces on each catalog and cart line, the transparency problem repeats every time you add a SKU or move tiers.

The delay disappears when drug cost is visible at the point of decision. Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a disclosed facilitation fee at payment and $0/mo plus pass-through pricing and 9% facilitation — so a clinician can quote a patient in the room and an owner can model margin from real numbers without committing to a $997/mo catalog gate first.

Pass-through pricing is the structural difference: instead of SaaS tiers plus opaque fulfillment layers, you see the 503A cost and the named fee. The evaluation test is whether you can answer what does this vial cost without a tier upgrade or a sales call. When the catalog answers that question, the consult keeps moving.